Botulinum toxin in the treatment of facial synkinesis and hyperkinesis

Laryngoscope

Volumn 122, Issue 2, 2012, Pages 266-270

  Filipo, Roberto ^a   Spahiu, Irma ^a   Covelli, Edoardo ^a   Nicastri, Maria ^a   Bertoli, Gian Antonio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

botulinum toxin; facial palsy; hyperkinesis; Level of Evidence: 1b; Synkinesis

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; BELL PALSY; CLINICAL ARTICLE; CLINICAL TRIAL; DIPLOPIA; DRUG EFFICACY; DRY EYE; FACE DISORDER; FACIAL NERVE PARALYSIS; FEMALE; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERKINESIA; IATROGENIC DISEASE; LAGOPHTHALMOS; MALE; MELKERSSON ROSENTHAL SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PTOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SYMPTOMATOLOGY; SYNKINESIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FACE; FACIAL MUSCLES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERKINESIS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; SYNKINESIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856274877     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.22404     Document Type: Article

References (15)

1. Laskawi,. The use of botulinum toxin in head and face medicine: an interdisciplinary field. Head Face Med 2008; 10; 4: 5.
2. Armstrong MWJ, Mountain RE, Murray JA,. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol 1996; 21: 15-20. (Pubitemid 26070326)
3. May M,. The Facial Nerve. New York, NY: Thieme Inc.; 1986.
4. Laskawi R, Damenz W, Roggenkamper P, Baetz A,. Botulinum toxin treatment in patients with facial synkinesis. Eur Arch Otorhinolaryngol 1994;(suppl): S195-S199.
5. Roggenkamper P, Laskawi R, Damenz W, Schroder M, Nubgens Z,. Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol 1994; 86: 395-402. (Pubitemid 24322984)
6. Jankovic J, Brin MF,. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186-1194.
7. Comella JX, Molgo J, Faille F,. Sprouting of mammalian motor nerve terminals induced by in vivo injection of botulinum type-D toxin and the functional recovery of paralysed neuromuscular junctions. Neurosci Lett 1993; 153: 61-64. (Pubitemid 23147037)
8. Setler PE,. Therapeutic use of botulinum toxins: background and history [review]. Clin J Pain 2002; 18 (6 suppl): S119-S124. (Pubitemid 35285594)
9. Scott AB, Rosenbaum A, Collins CC,. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924-927.
10. Frueh BR, Felt DP, Wojno TH, Musch DC,. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch Ophthalmol 1984; 102: 1464-1468. (Pubitemid 14048632)
11. Ross BG, Fradet G, Nedzelski JM,. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg 1996; 114: 380-386. (Pubitemid 26097125)
12. Mehta RP, Wernick Robinson M, Hadlock TA,. Validation of the Synkinesis Assessment Questionnaire. Laryngoscope 2007; 117: 9223-9226.
13. May M,. Microanatomy and pathophysiology of the facial nerve. In: The Facial Nerve. New York, NY: Thieme Inc.; 1986.: 69-72.
14. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S,. Severe botulism after focal injection of botulinum toxin. Neurology 2006; 67: 1855-1856. (Pubitemid 44900768)
15. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N,. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 1990; 37: 799-808. (Pubitemid 20282217)